Kitabis Pak Access Now Expanded for Many States

Kitabis Pak (tobramycin inhalation solution) is now on the Preferred Drug List (PDL) for many state programs, expanding its access for patients with cystic fibrosis (CF) using nebulized antibiotic therapy. It is indicated for the management of cystic fibrosis in adults and pediatric patients ≥6 years old with Pseudomonas aeruginosa.

Kitabis Pak contains a 28-day course of Tobramycin inhalation solution and the PARI LC Plus nebulizer handset. It is the therapeutic equivalent of Tobi (tobramycin inhalation solution; Novartis). Tobramycin is an aminoglycoside antibiotic that acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death.

RELATED: FDA Approves Unique Treatment for Cystic Fibrosis

Kitabis Pak is a co-packaged kit supplied as cartons containing one reusable PARI LC Plus nebulizer and 14 Tobramcyin inhalation solution pouches. Each pouch contains four 300mg/5mL ampules.

For more information call (844) 548-2247 or visit